WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526521
CAS#: 72818-36-1
Description: UK 34787 is a thromboxane inhibitor.
Hodoodo Cat#: H526521
Name: UK 34787
CAS#: 72818-36-1
Chemical Formula: C15H17N3
Exact Mass: 239.14
Molecular Weight: 239.322
Elemental Analysis: C, 75.28; H, 7.16; N, 17.56
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: UK 34787, UK-34787, UK34787
IUPAC/Chemical Name: 3-((1H-imidazol-1-yl)methyl)-2-isopropyl-1H-indole
InChi Key: NZXGMVRYQLENHC-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H17N3/c1-11(2)15-13(9-18-8-7-16-10-18)12-5-3-4-6-14(12)17-15/h3-8,10-11,17H,9H2,1-2H3
SMILES Code: CC(C(N1)=C(CN2C=CN=C2)C3=C1C=CC=C3)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 239.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Gresele P, Blockmans D, Deckmyn H, Vermylen J. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. J Pharmacol Exp Ther. 1988 Jul;246(1):301-7. PubMed PMID: 3134542.
2: Heptinstall S, Fox SC. Human blood platelet behaviour after inhibition of thromboxane synthetase. Br J Clin Pharmacol. 1983;15 Suppl 1:31S-37S. PubMed PMID: 6401998; PubMed Central PMCID: PMC1427694.
3: Peacock I, Hawkins M, Heptinstall S. Platelet behaviour in non-insulin-dependent diabetes--influence of vascular complications, treatment and metabolic control. Thromb Haemost. 1986 Jun 30;55(3):361-5. PubMed PMID: 3092392.
4: Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res. 1980 Oct 15;20(2):219-30. PubMed PMID: 7193919.
5: Carey F, Haworth D. Thromboxane synthase inhibition: implications for prostaglandin endoperoxide metabolism. II. Testing the 'redirection hypothesis' in an acute intravenous challenge model. Prostaglandins. 1986 Jan;31(1):47-59. PubMed PMID: 3754057.
6: Haworth D, Carey F. Thromboxane synthase inhibition: implications for prostaglandin endoperoxide metabolism. I. Characterisation of an acute intravenous challenge model to measure prostaglandin endoperoxide metabolism. Prostaglandins. 1986 Jan;31(1):33-45. PubMed PMID: 3081969.
7: Hornby EJ, Skidmore IF. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production. Biochem Pharmacol. 1982 Mar 15;31(6):1158-60. PubMed PMID: 7200773.